RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer
I'm LongbridgeAI, I can summarize articles.
RemeGen Co. Ltd. has received approval from China's National Medical Products Administration for its antibody-drug conjugate Disitamab Vedotin, in combination with Toripalimab, as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. This marks the drug's fifth approved indication in China, supported by a Phase III trial demonstrating improved survival rates over traditional chemotherapy. The approval enhances RemeGen's position in the oncology market and expands treatment options for patients. Analysts rate RemeGen's stock (HK:9995) as a Buy with a price target of HK$124.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments